Objectives: The AtLaS-M randomized trial showed that in patients with HIV-1 RNA ,50 copies/mL on atazanavir/ ritonavir ! two NRTIs, switching to a dual therapy with atazanavir/ritonavir!lamivudine had superior efficacy as compared with continuing the previous triple therapy. This substudy was designed to evaluate at 48 weeks the impact of the dual therapy versus the three-drug atazanavir/ritonavir-based therapy on the HIV-1 cellular reservoir as reflected by the quantification of blood-associated HIV-1 DNA levels.
Introduction
AtLaS-M was a randomized trial designed to evaluate the efficacy and safety of simplifying treatment to a dual regimen based on atazanavir/ritonavir!lamivudine as a single NRTI, as compared with continuing a triple atazanavir/ritonavir-based therapy in virologically controlled HIV-1-infected patients. At 48 weeks, the dual therapy was virologically superior and well tolerated. 1 These findings confirmed the promising results of the previous single-arm AtLaS pilot study 2, 3 and were consistent with those of the SALT randomized trial. 4 Nevertheless, the effects of the dual atazanavir/ ritonavir!lamivudine strategy on the HIV-1 reservoir are not yet well characterized. The quantification of total HIV-1 DNA levels in peripheral blood cells is generally accepted as an estimate of the cellular reservoir size; 5 it is useful to monitor the viral burden of HIV in selected sets of patients and it could provide important indications regarding the ability of the simplification strategy to prevent replenishment of the viral reservoir. Indeed, the level of bloodassociated HIV-1 DNA has been related to virological failure at initiation of combination ART (cART) 6 and has been found to predict time to virological rebound at cART interruption. 7 Moreover, it has been shown that baseline HIV-1 DNA levels decrease over time in concordance with a successful cART. 8, 9 Furthermore, HIV-1 DNA at the switch has been identified as a predictor of virological outcome in chronic patients who switched to a simplified PI monotherapy. 10, 11 In the single-arm AtLaS pilot study, we found that patients who switched to atazanavir/ritonavir!lamivudine appeared to undergo a decline in HIV-1 DNA after 48 weeks. 12 Our objectives here were to compare the impact of 48 weeks of atazanavir/ritonavir!lamivudine dual therapy versus maintaining atazanavir/ ritonavir ! two NRTIs on HIV-1 DNA levels and to analyse factors associated with the HIV-1 DNA levels in the AtLaS-M trial.
Patients and methods
AtLaS-M is a Phase IV, multicentre, open-label study. Overall 266 HIV-1-infected patients on cART with two NRTIs ! atazanavir/ritonavir without previous virological failures, with HIV-1 RNA ,50 copies/mL for .3 months and CD4 .200 cells/mm 3 for .6 months were randomized to switch to 300 mg/100 mg of atazanavir/ritonavir ! 300 mg of lamivudine once daily or to continue the previous regimen (ClinicalTrials.gov: NCT00885482). 1 The current substudy included a subset of 201 patients for whom whole blood samples were available at both baseline and week 48 (W48): 104 patients randomized to the dual-therapy arm and 97 patients randomized to maintain the triple therapy. DNA was isolated from whole blood using the QIAmp DNA blood mini kit (Qiagen, Hilden, Germany) according to the manufacturer's recommendations. Total HIV-1 DNA was quantified at baseline and at W48 using a TaqMan Real-Time PCR assay, targeting a conserved region of the HIV-1 5 0 long terminal repeat, as previously described. 9 The reaction was performed using Eco-Real Time PCR System (Illumina, Inc., San Diego, CA, USA). Real-Time PCR for the b-globin gene was analysed in a parallel run to normalize for the amount of cellular DNA in all samples. HIV-1 DNA levels were log transformed to approximate the normal distribution and expressed as number of copies per 10 6 leucocytes. HIV-1 DNA levels and changes in HIV-1 DNA levels from baseline to W48 were compared using parametric tests (t-test and paired-samples t-test). The association of variables with baseline HIV-1 DNA levels and HIV-1 DNA changes was analysed by linear regression. Residual viraemia was defined as any value of plasma HIV-1 RNA ,50 copies/mL using a real-time PCR assay (VERSANT HIV-1 RNA kPCR, Siemens Diagnostics, USA) with a lower limit of detection of 1 copy/mL; here residual viraemia was categorized as either detectable (1-49 HIV-1 RNA copies/mL) or undetectable (,1 HIV-1 RNA copy/mL). We defined viral rebound as any HIV-1 RNA determination 50 copies/mL that occurred during the 48 weeks, including both single blip and protocol-defined virological failure (two consecutive HIV-1 RNA levels 50 copies/mL or a single level 1000 copies/mL). Logistic regression and Cox proportional hazard models were used to predict the effects of baseline HIV-1 DNA levels on risk of residual viraemia at W48 and viral rebound, respectively. Statistical analysis was performed using SPSS software (version 17.0, Chicago, IL, USA).
Results
The baseline characteristics of the subset of patients included in this substudy were similar between arms and were consistent with those of the entire cohort (Table 1) . At baseline, HIV-1 DNA levels did not differ between the dual-therapy arm [2.47 (95% CI 2.37-2.57) log 10 copies/10
6 leucocytes] and the triple-therapy arm [2.46 (95% CI 2.35-2.58) log 10 copies/10
6 leucocytes] (P " 0.918). Moreover, a similar proportion of patients with undetectable plasma viraemia was found: 34.6% in the dual-therapy arm and 37.1% in the triple-therapy arm (P " 0.705). A similar significant mean HIV-1 DNA change from baseline to W48 was observed in both arms: #0.069 (95% CI #0.14 to #0.001, P " 0.046) log 10 copies/10 6 leucocytes in the dual-therapy arm versus #0.078 (95% CI The P values refer to differences between the two study arms. There was no significant difference in baseline characteristics between the patients included in this study (n " 201) and the complete AtLaS-M study cohort (n " 266).
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#0.14 to #0.019, P " 0.011) log 10 copies/10 6 leucocytes in the triple-therapy arm, with no significant differences between arms (mean difference 0.009, P " 0.842). Similar HIV-1 DNA levels were observed between groups at W48 (P " 0.836) (Figure 1 ). We found that CD4! T cell counts at nadir were inversely correlated with baseline HIV-1 DNA (per !100 cells/mm 3 , mean change -0.060 log 10 copies/10 6 leucocytes, 95% CI -0.104 to -0.015, P " 0.009); however, the current CD4 cell count was not associated with HIV-1 DNA levels. In the univariate analysis longer duration of previous cART exposure (per !1 year mean change !0.010, 95% CI 0.001-0.019, P " 0.031) and nadir CD4 (per !100 cells/mm 3 mean change #0.028, 95% CI #0.056 to #0.0001, P " 0.049) were associated with HIV-1 DNA changes from baseline at W48. No significant change was observed in residual viraemia: most of the patients maintained viral suppression at W48, with 31% and 28% of them showing undetectable HIV-1 RNA levels in the dualtherapy arm and the triple-therapy arm, respectively (McNemar's test, P " 0.481 and P " 0.405). Higher baseline HIV-1 DNA levels were associated with an increased likelihood of having detectable W48 residual viraemia (OR " 1.85; 95% CI 1.038-3.320, P " 0.037). During the study, 2 protocol-defined virological failures and 11 blips occurred in the triple-therapy arm and 8 blips and 0 virological failures were observed in the dual-therapy arm, with no difference between arms (P " not significant). Baseline HIV-1 DNA level was not a predictor of time to viral rebound when both blips and virological failures were considered (HR " 1.00; 95% CI 0.451-2.213, P " 0.998).
Discussion
An observation in the previous AtLaS pilot substudy suggested that the switch to atazanavir/ritonavir!lamivudine had potentially favourable effects on the HIV-1 DNA levels of virologically suppressed patients. 12 Here we demonstrate that, after 1 year of treatment, this simplification strategy had the same impact on the cellular viral reservoir as continuation of the atazanavir/ritonavir ! two NRTIs regimen. Indeed, parallel and comparable changes in HIV-1 DNA levels were observed in the two study arms.
The HIV-1 DNA reductions observed were consistent with those previously reported in a few longitudinal studies that explored the long-term HIV-1 DNA level evolution during standard effective ART, 8, 9 where different stages of HIV-1 DNA decay occurred; in particular, a rapid decrease in the first year after cART initiation was observed, followed by a slower decay up to years 3-4 and a subsequent plateau phase. Accordingly, our patients, who had been exposed to cART for a median of 2.5 years, showed a minimal but significant overall mean reduction of HIV-1 DNA levels after 1 year of observation that was close to that previously reported. Accordingly, the longer duration of previous ART exposure was associated with a slower decline at W48.
We found an inverse association between baseline HIV-1 DNA and CD4 nadir, consistent with previous findings; 10, 13 in addition, the reduction in HIV-1 DNA levels was significantly smaller in patients with a lower CD4 nadir. Patients exposed longer to HIV HIV-1 DNA in atazanavir/ritonavir!lamivudine dual therapy JAC before they began cART had probably reached more profound CD4 cell depletion, which has been shown to be accompanied by increased levels of HIV-1 DNA in blood cells.
Taken together, these data seem to indicate that, in chronically infected patients, after cART HIV-1 DNA reaches levels that are at least partly determined by the pre-treatment immune status. This underscores the importance of early cART initiation.
HIV-1 DNA levels have been shown to be an independent predictor of virological rebound in patients whose treatment was simplified from cART to monotherapies with boosted PI. 10, 11 In our study the low frequency of blips and of virological failures may be an explanation of the failure to detect a relationship between HIV-1 DNA levels and viral rebound. On the other hand, we found that baseline HIV-1 DNA levels were higher in subjects with detectable residual plasma viraemia than in those with undetectable viraemia at follow-up, suggesting a potential predictive value of HIV-1 DNA on ongoing low-level viral replication or release from the viral reservoir. In a previous cross-sectional analysis Chun et al.
14 also indicated that greater size of the CD4 T cell viral reservoir was associated with detectable plasma viraemia.
In conclusion, we demonstrated that the evolution of bloodassociated HIV-1 DNA levels in virologically suppressed patients on atazanavir/ritonavir ! two NRTIs remained similar after they switched to a dual therapy with atazanavir/ritonavir!lamivudine. Our finding indicates that as maintenance therapy this drug reduction strategy is effective in avoiding replenishment of the cellular reservoir.
